恒瑞医药富马酸泰吉利定注射液临床试验获批

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of Fumaric Acid Tegeline Injection, aimed at providing analgesia for patients on mechanical ventilation in intensive care [1] Company Summary - Fumaric Acid Tegeline Injection is a μ-opioid receptor (MOR) biased small molecule agonist [1] - The product is set to be approved for domestic market launch in January 2024, marking it as China's first independently developed Class 1 innovative opioid analgesic [1]